The correlation seems strong,
"Nevertheless, the authors caution that the study’s observational, cross-sectional nature precludes definitive causal inferences."
2/2
In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged primarily as breakthrough medications targeting metabolic disorders such as type 2 diabetes and obesity. Medications
